Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD
Status:
Completed
Trial end date:
2012-02-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if 12 weeks' treatment with GSK573719 Inhalation
Powder is safe and effective compared with placebo or no active drug intake, when
administered once-daily in subjects with Chronic Obstructive Pulmonary Disease (COPD).